Alexander Zweibach
Hematology & Oncology · New Braunfels, TXNPI 1659343358
Payments from drug & device makers
Across 420 payments — averaging $301.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$116K
- Acerta Pharma LLC$5K
- Gilead$1K
- E.r. Squibb & Sons, L.L.C.$393
- Genentech USA, Inc.$381
- Novartis$377
- plus $3K from 35 others
Across 1 payment — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerta Pharma LLC$1K
What the payments were for
- Consulting fees$1,13022%
- Food & beverage$3,69771%
- Education$3867%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 145 | $116,372 |
| Acerta Pharma LLC | 2 | $5,000 |
| Gilead(2 entities) | 4 | $1,170 |
| E.r. Squibb & Sons, L.L.C. | 37 | $393 |
| Genentech USA, Inc. | 31 | $381 |
| Novartis | 22 | $377 |
| Johnson & Johnson(2 entities) | 21 | $371 |
| Seagen Inc. | 8 | $194 |
| Incyte Corporation | 10 | $190 |
| Merck | 14 | $178 |
| Pfizer | 17 | $172 |
| Sanofi | 10 | $160 |
| Amgen | 8 | $151 |
| AstraZeneca(2 entities) | 10 | $140 |
| Eisai Inc. | 8 | $136 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $118 |
| Lilly USA, LLC | 14 | $115 |
| Bristol Myers Squibb | 6 | $104 |
| Astellas Pharma US Inc | 5 | $76 |
| Bayer | 4 | $75 |
| Verastem, Inc. | 4 | $73 |
| Tersera Therapeutics LLC | 3 | $63 |
| Dendreon Pharmaceuticals LLC | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Puma Biotechnology, Inc. | 3 | $48 |
| Dova Pharmaceuticals | 2 | $46 |
| AbbVie | 2 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Karyopharm Therapeutics Inc. | 2 | $32 |
| EMD Serono, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Array Biopharma Inc | 2 | $28 |
| Rigel Pharmaceuticals, Inc. | 2 | $24 |
| Exelixis Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Sandoz | 1 | $13 |
| Taiho Oncology, Inc. | 1 | $11 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,585 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in New Braunfels
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.